Publications

Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in…

First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid…

The HALO Study: A Phase I-II of the Oral HSP90 Inhibitor Debio 0932 in combination with SOC in First- and…

A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell…

Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid…

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results

Preclinical Pharmacokinetics and Efficacy of Debio 1450 (Previously AFN-1720), a Prodrug of the Staphylococcocal-specific Antibiotic Debio 1452 (Previously AFN-1252)

Tolerability, Safety and Pharmacokinetics in Healthy Subjects of Single Intravenous Doses of Debio 1450 (Previously AFN-1720), a Prodrug of the…

Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell…